Pfizer Inc. announced today that it will present data for several of its marketed and investigational medicines for inflammatory and immunological conditions at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2014 Annual Meeting (November 14-19, Boston, Massachusetts).
Via Krishan Maggon
Improvement of disease activity and reduction of severe flares following subcutaneous administration of an IL-6 monoclonal antibody (mAb) in subjects with active generalized systemic lupus erythematosus (SLE)." Wallace DJ, Popa S, Spindler AJ, et. al. [Presentation L3; November 18, 2014 5:00 p.m. - 5:15 p.m.]